Healius Limited · ASX:HLS

Paul Anderson sold 17,388 Healius Limited shares (Appendix 3Y, ASX)

Traded Nov 17, 2026 · Filed Nov 18, 2026

On Nov 17, 2026, Paul Anderson (Director) sold 17,388 Healius Limited shares at AUD 0.43 for AUD 7,477. Filed Nov 18, 2026 (Appendix 3Y, ASX).

Sold
17,388 shares
Price
AUD 0.43
Value
AUD 7,477
Role
Director

The filing in full

ASX Announcement

18 November 2026

ASX Limited

Market Announcements Office

39 Martin Place

SYDNEY NSW 2000

Re: Healius Limited (‘HLS’): Late lodgement of Appendix 3Y – Paul Anderson

The Company wishes to notify the ASX that a Director's Appendix 3Y is being lodged outside the required
timeframes under the ASX Listing Rules.

We now enclose the Appendix 3Y for lodgement and have outlined below an explanation as to why this occurred.

On 26 October 2026, an adviser's platform sold 8,694 shares held indirectly by the Director without his knowledge
or authority. Upon becoming aware of the transaction, the Director promptly repurchased the same number of
shares, restoring his holding to the number disclosed in his previous Appendix 3Y.

As neither the Director nor the Company was notified of the disposal at the time it occurred, the Appendix 3Y was
not lodged within the five-business-day period required by ASX Listing Rule 3.19A.2.

The Company considers this to be an isolated incident and that its existing arrangements with Directors for
notification of changes in their interests (including under its ‘Policy on Trading in Healius Securities’) are
appropriate. The Director has also engaged with his adviser regarding appropriate processes to be applied should
a similar situation arise in the future.

This announcement has been authorised for release by the Managing Director and CEO.

For further information please contact:

Investor Enquiries

Andrew Thomson

Media Enquiries

Chief Financial Officer

Healius Limited

investor.relations@healius.com.au

Susannah Rands

Head of Communications

Healius Limited

media@healius.com.au

About Healius Limited

*For over 30 years Healius has been one of Australia’s leading healthcare companies, committed to supporting
quality, affordable and accessible healthcare for all Australians. Through its unique footprint of centres and its*
*8,500+ employees, Healius provides Australia-wide specialty pathology services to consumers and their referring
practitioners.*

---

*Rule 3.19A.2*

Appendix 3Y

Change of Director’s Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entityHEALIUS LIMITED
ABN24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.

Name of DirectorPaul Anderson
Date of last notice27 October 2026

Part 1 - Change of director’s relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.

Direct or indirect interestDirect and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.The Director has an indirect interest in fully paid ordinary shares in Healius Limited acquired by the Tuis Farm Family Trust as he is a beneficiary of the Trust.
Date of change26 October 2026 inadvertent sale 17 November 2026 re-purchase
No. of securities held prior to changeDirect 37,837 Ordinary Shares 4,469,109 Performance Rights 117,433 Service Rights Indirect 344,843 Ordinary Shares
ClassFully paid ordinary shares
Number acquired8694
Number disposed8694
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation$0.43 per share inadvertently sold $0.585 per share re-purchased

---

No. of securities held after changeDirect 37,837 Ordinary Shares 4,469,109 Performance Rights 117,433 Service Rights Indirect 344,843 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-backThe securities were mistakenly sold by the Director's adviser. The Director re-purchased the securities on becoming aware of the decrease in holding.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.

Detail of contractN/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

+ Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?No
If so, was prior written clearance provided to allow the trade to proceed during this period?N/A
If prior written clearance was provided, on what date was this provided?N/A

Authorised by:
Kylie Brown
Company Secretary
Date: 18 November 2026

  • See chapter 19 for defined terms.
DateSecurityTransactionSharesPriceHolding afterOwnership
Nov 17, 2026Fully paid ordinary sharesSale8,694AUD 0.43
Nov 17, 2026Fully paid ordinary sharesSale8,694AUD 0.43

Source

Download PDF · View original at ASX

Related